Myron S. Cohen
Fred Hutchinson Cancer Center
Public scientific profile · Unclaimed
Built from public scholarly sources. Expertise is inferred by ScienceWe from publications and has not been confirmed by the scientist.
Top expertise
HIV Research and Treatment
Strong evidence · 13 supporting papers · latest 2026
HIV/AIDS Research and Interventions
Strong evidence · 8 supporting papers · latest 2026
HIV/AIDS drug development and treatment
Strong evidence · 10 supporting papers · latest 2026
SARS-CoV-2 and COVID-19 Research
Solid evidence · 1 supporting paper · latest 2026
Monoclonal and Polyclonal Antibodies Research
Solid evidence · 3 supporting papers · latest 2026
vaccines and immunoinformatics approaches
Solid evidence · 3 supporting papers · latest 2026
Clinical Laboratory Practices and Quality Control
Solid evidence · 1 supporting paper · latest 2026
Medical Device Sterilization and Disinfection
Supporting evidence · 1 supporting paper · latest 2026
Publications (16)
Long-read deep sequencing reveals high rates of multilineage transmission and rapid viral population changes in acute HIV infection
2026DOIPMID 41279611
Treatment as Prevention and HIV Transmission in the US
2026DOIPMID 42627660
VRC01 Exerted Differential Pressure on HIV-1 Envelope From Subtypes B and C That Continued in the First Weeks Postdiagnosis in the Antibody Mediated Prevention Trials
2026DOIPMID 42708883
Analytical treatment interruption among women with HIV in southern Africa who received VRC01 or placebo in the Antibody Mediated Prevention Study: ATI stakeholder engagement, implementation and early clinical data
2026DOI
Safety, pharmacokinetics, and neutralisation activity of PGDM1400LS, a V2 specific HIV-1 broadly neutralising antibody, infused intravenously or subcutaneously in people without HIV-1 in the USA (HVTN 140/HPTN 101 part A): a first-in-human, phase 1 randomised trial
2026DOI
Sequencing HIV diagnostic samples to detect genetic clusters and assess sequence coverage gaps
2026DOI
HIV-phyloTSI: subtype-independent estimation of time since HIV-1 infection for cross-sectional measures of population incidence using deep sequence data
2026DOI
Fixed dosing versus weight-based dosing of HIV-1 prophylactic monoclonal antibodies in adults: a post-hoc, cross-protocol pharmacokinetics modelling study
2026DOI
Prospective HIV RNA Screening With Long-acting Cabotegravir Pre-exposure Prophylaxis in HPTN 083
2026DOIPMID 42044061
Safety, pharmacokinetics, and neutralisation activity of PGDM1400LS, VRC07-523LS, and PGT121.414.LS infused intravenously or subcutaneously (HVTN 140/HPTN 101 part B): a phase 1, randomised trial
2026DOIPMID 42114530
mRNA-1273 SARS-CoV-2 vaccination in people with HIV: an immune correlates analysis of CD4 + T cell responses in the multicenter CoVPN 3008 observational study
2026DOI
HPTN 052, the PARTNER Study, and the Dawn of Treatment as Prevention
2026DOI
HIV low‐level viraemia: considerations for prevention and treatment in an era of highly effective and durable antiretroviral therapy regimens
2026DOIPMID 41733000
Influence of the broadly neutralizing antibody VRC01 on HIV breakthrough virus populations in antibody-mediated prevention trials
2026DOI
Long-read deep sequencing reveals high rates of multilineage transmission and rapid viral population changes in acute HIV infection
2026DOI
Organizations in sourced records
Affiliation evidence only — not confirmed current employment.
- Fred Hutchinson Cancer Center
Source: OpenAlex · retrieved 2026-09-29
Source: ScienceWe Extractor · retrieved 2026-09-27